Plus   Neg

Keep An Eye On ALDX Today


Aldeyra Therapeutics Inc. (ALDX) is scheduled to report results from its phase IIb clinical trial of topical ocular ADX-102 in allergic conjunctivitis on Wednesday, June 14, 2017, before the market opens.

Allergic conjunctivitis, also known as pink eye, is a condition where the conjunctiva of the eye becomes inflamed due to allergic reactions. Allergic conjunctivitis, which affects an estimated 20% to 40% of the population worldwide, is characterized by itchiness, redness, and excessive tear production.

Last February, the Company reported positive data from its phase IIa trial of ADX-102 ophthalmic solution in patients with allergic conjunctivitis. ADX-102 clinically improved ocular itching and tearing scores after acute administration and after 14 days of dosing in the phase IIa trial.

A phase IIb clinical trial of ADX-102 for the treatment of allergic conjunctivitis started in February of this year, and the last patient completed dosing as recently as April. The study has enrolled a total of 150 patients.

The trial tested 0.1% and 0.5% concentrations of topical ocular ADX-102 against saline. Patient-reported ocular itching is set as the primary endpoint.

Will the phase IIb results, scheduled to be reported today, boost investor sentiment or will it only give them an itch to switch?

Aldeyra shares, which are down more than 4% year-to-date, closed Tuesday's trading at $5.10, up 0.99%. In after-hours, the stock was up 3.92% at $5.30.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT